Tracking a blood marker in children with lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study checks whether measuring a blood test called “circulating tumor DNA” (ctDNA) helps monitor childhood lymphoma during treatment. It’s meant to see if ctDNA tracking can provide useful information alongside standard exams.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are under 18 and have pediatric lymphoma (either Hodgkin lymphoma or non-Hodgkin lymphoma).
- Your energy/ability score from ECOG is 0 to 2 (meaning you can do daily activities with limited help).
- Your doctors have found at least one measurable lymph node/lesion on CT or MRI (at least 1.5 cm) that can be measured more than one way.
- You can provide required blood samples (and any needed tissue/bone marrow/cerebrospinal fluid samples) at the start and throughout follow-up.
- All needed baseline test results and pathology (tissue diagnosis details) are available, and you can be evaluated on schedule.
- You (or your legal parent/guardian) can sign informed consent after learning about the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new way to monitor how well your lymphoma treatment is working. It uses a blood test to look for genetic changes in cancer cells, which may help doctors make better treatment decisions.
This trial studies whether using a blood test (ctDNA) can help guide treatment decisions for people with newly diagnosed diffuse large B-cell lymphoma. It tests standard chemotherapy regimens (R-CHOP or R-pola-CHP) and aims to improve outcomes by monitoring tumor DNA in the blood.
This trial looks at a blood test (ctDNA) to track post-transplant lymphoproliferative disorder (PTLD). It tests how well ctDNA measures treatment response and may help guide future care.
This study collects blood samples from neuroblastoma patients to test for tiny pieces of tumor DNA that can show how well treatment is working. By tracking these markers over time, doctors hope to better predict how patients will respond and improve care.
This study uses a blood test to detect cancer DNA (ctDNA) in children and young adults with classical Hodgkin lymphoma. The goal is to see if this non-invasive test can help track how well treatment is working.
This study looks at whether a simple blood test that measures tumor DNA (called ctDNA) can track how well treatment is working in children with acute leukemia. The goal is to see if the blood test can give the same information as a bone marrow test, which is more invasive.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.